MedTrace Logo

Intratumoral Cisplatin for Resectable NSCLC

NCT04809103 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-02-06

Study results available
· View outcomes & findings →

Summary

PRIMARY OBJECTIVE:

To identify the maximum tolerated dose (MTD) of intratumoral cisplatin, delivered during a single bronchoscopy with cone-beam CT confirmation, in a dose escalation protocol

DESIGN: 3+3 dose escalation.

Conditions

Interventions

DRUG

cis-diamminedichloroplatinum

Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC

Sponsors & Collaborators

Principal Investigators

  • C. Matthew Kinsey, MD, MPH · University of Vermont

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-08
Primary Completion
2025-10-01
Completion
2025-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04809103 on ClinicalTrials.gov